Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Possis

This article was originally published in The Gray Sheet

Executive Summary

Possis: Gains CE Mark approval for the AngioJet rapid thrombectomy system for peripheral applications and the Perma-Seal dialysis access graft. CE mark approval is pending for coronary applications of the AngioJet System and for the Perma-Flow coronary bypass graft. The AngioJet was cleared by FDA in December 1996 and a 510(k) for the Perma-Seal is pending at FDA ("The Gray Sheet" June 17, 1996, In Brief)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT008280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel